Navigation Links
Halozyme Therapeutics to Host Research Day for Investors and Analysts
Date:10/1/2008

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a Research Day on Wednesday, October 8, beginning at 12:15 p.m. EDT. A webcast of the presentations will be available live on the company website.

PRESENTATIONS

-- Strategic Company Overview, Jonathan Lim, M.D., President and Chief Executive Officer

-- Science and Technology Overview, Gregory Frost, Ph.D., Vice President and Chief Scientific Officer

-- Insulins -- Faster Acting, Regular and Analog, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development

-- Bisphosphonates -- Advantages of Subcutaneous Injection with rHuPH20, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development

-- PEGPH20 -- A Targeted Therapy for Cancer Treatment, Patrick O'Connor, Ph.D., Vice President, Research

-- Chemophase -- Next Steps to Pivotal Trials, Richard C. Yocum, M.D., Vice President, Clinical Development and Medical Affairs

-- Commercial Opportunities -- The Value Proposition, Robert L. Little, Vice President and Chief Commercial Officer

Halozyme will conduct a live webcast of the presentations beginning at 12:15 p.m. EDT. To access the webcast over the internet, please go to the company website at http://www.halozyme.com. An archive of the presentation will be available on Halozyme's website shortly after the conclusion of the meeting.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact Media Contacts

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Mentus

Investor Relations (858) 455-5500, x275/x215

(858) 704-8264 karen@mentus.com

ruhl@halozyme.com jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
6. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
7. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
11. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):